Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor - Wikidata - wikimedia - TriplyDB

Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor

Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor

http://www.wikidata.org/entity/Q28277631

about

Syndecans: multifunctional cell-surface co-receptors The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading Midkine and cytoplasmic maturation of mammalian oocytes in the context of ovarian follicle physiology Structure and function of midkine as the basis of its pharmacological effects Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase A Receptor-like Protein-tyrosine Phosphatase PTP /RPTP Binds a Heparin-binding Growth Factor Midkine: INVOLVEMENT OF ARGININE 78 OF MIDKINE IN THE HIGH AFFINITY BINDING TO PTP Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.The cumulus cell gene expression profile of oocytes with different nuclear maturity and potential for blastocyst formation Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells.Midkine: a promising molecule for drug development to treat diseases of the central nervous system Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.The advances of Midkine with peripheral invasion in pancreatic cancer.A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280.Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey.TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity.Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system.Midkine: a novel prognostic biomarker for cancer.Tissue factor pathway inhibitor: structure-function.The heparin-binding growth factor midkine: the biological activities and candidate receptors.Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells.Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor.Identification of an adhesion site within the syndecan-4 extracellular protein domain.9-cis-retinoic acid during in vitro maturation improves development of the bovine oocyte and increases midkine but not IGF-I expression in cumulus-granulosa cells.Glycosaminoglycans differentially bind HARP and modulate its biological activity.Syndecan-4 deficiency increases susceptibility to kappa-carrageenan-induced renal damage.The two thrombospondin type I repeat domains of the heparin-binding growth-associated molecule bind to heparin/heparan sulfate and regulate neurite extension and plasticity in hippocampal neurons.Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors. A novel function to control bindin Midkine, a heparin-binding growth factor, is expressed in neural precursor cells and promotes their growth.Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis.The Role of Midkine in Arteriogenesis, Involving Mechanosensing, Endothelial Cell Proliferation, and Vasodilation

P2860

Q24530478-4320B702-4778-447C-9800-CDA0237E11FB Q24669779-A561B701-4080-421E-BDE9-C7B4FFE5BA2E Q27010676-51C2A9E2-8F52-4990-BC1C-4DB5493BE66D Q27013798-FDAAD99A-0F62-42BF-80AA-8C597AA66547 Q28208159-D1779E47-298C-481E-BB31-386BA873B78B Q28260810-F778D9B1-C2CD-483F-9CFF-CE2FC4F219C8 Q28565517-64486C27-0186-42B9-9ACE-8EE2C81B59CD Q29393598-89FCB22A-C182-4076-A61E-4BA3DB0FC3BA Q34114308-F7F41C4D-FDFC-4AE4-904B-D0E561AAD2CB Q34608678-988471B5-02BC-4220-8167-39CC558EA389 Q35548533-89EC87DC-1864-459F-BEFA-146D0ADD54EC Q35701268-BAC1024A-012C-46A2-BE20-240B4E6B83E2 Q36160231-23747B75-B395-4480-9429-E243D6E2C582 Q36250696-EB581C4D-3711-409C-A860-DC9247287935 Q36255171-0CACD3EB-BDE7-46C1-A26A-F3CFCAD09678 Q36489766-72FAFD6A-F38F-4C50-B652-86833725D673 Q36565141-65E42AEC-5F3A-4CCE-BFB3-CDC77A734AA2 Q36935686-305FB084-ED55-431B-BD29-4CF824AC3D0D Q37328317-5FBDE0AC-5B9E-42F9-9695-1AF92C508F53 Q37971520-AC1D3DB0-05DA-4048-A863-E55BE892DEC5 Q38102670-7A6E8BE2-934D-4A0D-B4B5-5364FE8FE568 Q38181600-A74C0F97-EF6F-47A3-BB5E-FF0C1D900A79 Q40874868-ECFCEF89-A965-46B5-A9BF-39DA575F6089 Q40911621-39A7E23C-2C85-415E-86D0-0A8D018EECF4 Q41109997-25CDA2C9-7FB7-42DD-AC94-24459C6CE965 Q41615626-4B237E9A-9685-4CD0-A966-85A15A3F263D Q42818531-898FE482-037E-4B27-BF6C-2F16F2396BE5 Q43576589-C3B74698-6D50-492A-8A75-82DD850E7F6F Q46696948-74E5A2B0-D68E-4021-B75F-6C7B48C2CF83 Q47265732-D64685FD-4693-42D8-9F5B-CB4F30158C7E Q48306474-9C2DE32B-447B-4FD3-84A1-4F1989D95A6F Q51797373-417141F7-DF91-41A2-BF11-B728A3043673 Q58692821-78ED2276-34FE-42A2-BF61-108A88C4FCB2

P2860

Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor

http://www.wikidata.org/entity/Q28277631

description

1996 nî lūn-bûn

@nan

1996 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի մարտին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Human ryudocan from endotheliu ...... issue factor pathway inhibitor

@ast

Human ryudocan from endotheliu ...... issue factor pathway inhibitor

@en

Human ryudocan from endotheliu ...... issue factor pathway inhibitor

@nl

type

label

Human ryudocan from endotheliu ...... issue factor pathway inhibitor

@ast

Human ryudocan from endotheliu ...... issue factor pathway inhibitor

@en

Human ryudocan from endotheliu ...... issue factor pathway inhibitor

@nl

prefLabel

Human ryudocan from endotheliu ...... issue factor pathway inhibitor

@ast

Human ryudocan from endotheliu ...... issue factor pathway inhibitor

@en

Human ryudocan from endotheliu ...... issue factor pathway inhibitor

@nl

P1433

Q28277631-4BFAB842-AB85-4922-8A34-0201EBF6F84E

P1476

Q28277631-43A7AF22-C639-475A-AE68-74121DA16D33

P2093

Q28277631-3A19EF38-3DC3-4CBE-8271-8F62291ACFBE

Q28277631-46B2DB40-9C01-4C70-996E-0D55A870D63A

Q28277631-94662E34-7789-4BB8-870B-A9D55B1DB004

Q28277631-DD682406-C925-45AA-8D8E-1C2357461BF7

Q28277631-DF9BBAC0-F4CA-431C-9A4E-7604725ECB7D

Q28277631-E362EA8B-7CA1-44D6-8003-7711A4537777

Q28277631-FCBE44E6-26DF-47DA-98E2-14B72C2C12BB

P2860

Q28277631-02E6D95A-5D9C-48BC-BB31-74D865891579

Q28277631-1ADDCCBA-913B-461B-8BA6-5C9408CAD8E5

Q28277631-25970792-CDDD-43A7-AADD-C525FE199110

Q28277631-2FB054A6-5AB2-45A2-A400-49C34CB0DB96

Q28277631-326AFAD8-B844-4BA5-8BD1-7B4A86C1A973

Q28277631-3B107D31-38DC-4309-AEA3-5B881B4158E4

Q28277631-43B635E0-DB01-44B1-A14F-8F531B3F3F77

Q28277631-4F16E1CA-BB33-4383-BA2F-A2C315BE6F44

Q28277631-62894F61-41F3-449C-901A-D5ACA6D4738F

Q28277631-93949990-05DA-4898-81E8-451BD8A2D984

P304

Q28277631-C48E82EC-E09B-4871-83D1-6221C2DEB872

P31

Q28277631-41479D4A-4A01-4F57-842B-CA3CE2A55A68

P356

Q28277631-2E2C02D3-9018-4ED1-96D3-FE06F4ECE778

P407

Q28277631-D5A3E084-CAC1-4C08-93FD-86478CD6FB40

P433

Q28277631-2C1BD36D-2889-4D01-8E12-D01885D3ABB8

P478

Q28277631-5663AFEE-4D3C-4A3E-9D24-FD4D838F68DE

P577

Q28277631-C50B9058-4346-4582-951C-15DB5E7F6580

P5875

Q28277631-2189D270-839F-4ADC-9A4A-D6A66781E22D

P698

Q28277631-D2ED3562-570B-4669-936F-7BEB01B1ECF7

P921

Q28277631-4FC16814-1DE8-4E5D-BF71-FA0B9B17CB74

P356

JBC.271.10.5914

P1433

Journal of Biological Chemistry

P1476

Human ryudocan from endotheliu ...... issue factor pathway inhibitor

@en

P2093

A Katsumi

http://www.w3.org/2001/XMLSchema#string

H Saito

http://www.w3.org/2001/XMLSchema#string

K Ohsumi

http://www.w3.org/2001/XMLSchema#string

T Kojima

http://www.w3.org/2001/XMLSchema#string

T Muramatsu

http://www.w3.org/2001/XMLSchema#string

T Nagasaka

http://www.w3.org/2001/XMLSchema#string

T Yamazaki

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning of amphiglycan, a novel integral membrane heparan sulfate proteoglycan expressed by epithelial and fibroblastic cells

Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity

Molecular cloning and characterization of N-syndecan, a novel transmembrane heparan sulfate proteoglycan

Molecular cloning of syndecan, an integral membrane proteoglycan

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix

Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor

Syndecan 3: a member of the syndecan family of membrane-intercalated proteoglycans that is expressed in high amounts at the onset of chicken limb cartilage differentiation.

Ligand-affinity cloning and structure of a cell surface heparan sulfate proteoglycan that binds basic fibroblast growth factor.

P304

5914-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.271.10.5914

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

271

http://www.w3.org/2001/XMLSchema#string

P577

1996-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14578024

http://www.w3.org/2001/XMLSchema#string

P698

8621465

http://www.w3.org/2001/XMLSchema#string

P921